166 related articles for article (PubMed ID: 36808043)
1. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
[TBL] [Abstract][Full Text] [Related]
2. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
3. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
4. Physical and cognitive correlates, inflammatory levels, and treatment response in post-COVID-19 first-onset vs. recurrent depressive episodes.
Di Nicola M; Pepe M; De Mori L; Ferrara OM; Panaccione I; Sani G
Eur Arch Psychiatry Clin Neurosci; 2024 Apr; 274(3):583-593. PubMed ID: 37154920
[TBL] [Abstract][Full Text] [Related]
5. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
6. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
7. Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma.
De Filippis S; Lombardozzi G; Matrone M; Amici E; Trovini G; Perrini F; Di Giovanni A; Giovanetti V; Kotzalidis GD
Curr Neuropharmacol; 2022 Nov; 20(12):2393-2407. PubMed ID: 35272591
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
9. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine
Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
[TBL] [Abstract][Full Text] [Related]
13. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
14. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
[No Abstract] [Full Text] [Related]
19. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]